Menveo FDA Approval History
FDA Approved: Yes (First approved February 19, 2010)
Brand name: Menveo
Generic name: meningococcal conjugate vaccine
Company: Novartis Vaccines and Diagnostics
Treatment for: Meningococcal Meningitis Prophylaxis
Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
Development Timeline for Menveo
|Aug 2, 2013||Approval FDA Expands Age Indication for Menveo|
|Jan 31, 2011||Approval FDA Approves the Novartis Quadrivalent Meningococcal Conjugate Vaccine, Menveo, for Use in Children From 2 Years of Age|
|Feb 22, 2010||Approval Novartis Gets US Approval for Menveo Meningitis Vaccine|
|Jul 1, 2009||Novartis Receives Complete Response Letter From The US Food And Drug Administration For Its Investigational Vaccine Menveo|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.